AN2 Therapeutics, Inc.
ANTX
$1.25
-$0.04-3.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 55.49% | 23.70% | 8.66% | -8.44% | -42.70% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.99% | -23.41% | -8.12% | -21.67% | -17.10% |
| Change in Net Operating Assets | 194.53% | -112.76% | -190.05% | -209.40% | -135.50% |
| Cash from Operations | 69.11% | -1.75% | -12.16% | -51.72% | -123.46% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,738.10% | 129.97% | 108.96% | 141.48% | -93.06% |
| Cash from Investing | -1,738.10% | 129.97% | 108.96% | 141.48% | -93.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -99.97% | -100.00% | 75.38% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.00% | -99.97% | -100.00% | 75.38% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.38% | 182.17% | -85.28% | 1,873.73% | -971.95% |